Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Other Non-Current Liabilities data on record, last reported at $135.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $135.0 million; the TTM value through Dec 2025 reached $135.0 million, changed N/A, while the annual FY2025 figure was $135.0 million, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $135.0 million in Q4 2025 per RCUS's latest filing, down from $152.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $166.0 million in Q1 2025 and bottomed at $10.2 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $100.1 million, with a median of $138.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 22367.77% in 2021, then decreased 6.21% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $122.0 million in 2021, then grew by 14.75% to $140.0 million in 2022, then grew by 1.43% to $142.0 million in 2023, then fell by 4.23% to $136.0 million in 2024, then decreased by 0.74% to $135.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $135.0 million in Q4 2025, $152.0 million in Q3 2025, and $159.0 million in Q2 2025.